Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2014. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMRs), and connected persons, in accordance with Disclosure and Transparency Rule (DTR) 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share allocation events rather than comprehensive financial performance.
Material Changes and Transaction Details
The filing reports an increase in the notional allocation of GSK American Depositary Shares (ADSs) on November 6, 2014. This adjustment followed the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction price was $44.75 per ADS.
- Director/PDMR Allocations:
- Mrs D P Connelly: 1 ADS
- Mr W C Louv: 24 ADSs
- Dr M M Slaoui: 17 ADSs
- Connected Person Allocations:
- Dr K Slaoui (connected to Dr M M Slaoui): 16 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Key Facts for Investor Verification
- Verify the impact of the 401K plan revaluation on the total notional holdings of the named directors.
- Confirm the trading price of $44.75 per ADS against market data for November 6, 2014.
- Review the full list of PDMR transactions for the quarter to assess overall insider trading activity.